Association of bleeding symptoms during influenza infection and administered drugs-Reference-Cited by-同舟云学术

Association of bleeding symptoms during influenza infection and administered drugs

Published:2021-10-31 Issue:5 Volume:15 Page:261-267
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Sugawara Tamie¹,Ohkusa Yasushi¹,Taniguchi Kiyosu²,Miyazaki Chiaki³,Kato Yoko⁴,Okabe Nobuhiko⁵

Affiliation:

1. Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan.

2. National Hospital Organization Mie National Hospital, Japan.

3. Fukuoka City Social Welfare Agency, Japan.

4. Division of Transfusion Medicine, Daisan Hospital, Department of Pediatrics, Jikei University School of Medicine, Japan.

5. Kawasaki City Institute for Public Health, Japan.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.jstage.jst.go.jp/article/ddt/15/5/15_2021.01085/_pdf

Reference33 articles.

1. 1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology (Cancer: Principles & Practice) 11th Edition. Wolters Kluwer Health, Philadelphia, USA, 2019, pp. 2074-2075.

2. 2. Garcia Rodriguez LA, Martin-Perez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: A systematic review of observational studies. PLoS One. 2016; 11:e0160046.

3. 3. O'Brien S. UpToDate: Approach to the child with bleeding symptoms. https://www.uptodate.com/contents/approach-to-the-child-with-bleeding-symptoms?search=bleeding%20symptoms&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 (accessed on April 2, 2021)

4. 4. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EGD, Muller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427:537-541.

5. 5. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot M. Cytochrome P450 2C9 (CYP2C9) and Vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005; 106:135-140.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system;BMC Infectious Diseases;2024-05-09

2. Antiviral influenza treatments and hemorrhage‐related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-04-24

3. Focus on the Hemorrhagic Risk of Anti-Influenza Agents: A Safety Analysis from Clinical Trials and Pharmacovigilance System;2023

4. Antivirals/paracetamol;Reactions Weekly;2022-09-24